Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Biography

Joël Richard is currently Senior Vice President of Peptides in IPSEN, France. He is globally leading all the pharmaceutical development activities of peptide-based products, including APIs and drug products, with major franchises in oncology, endocrinology and neurology. He has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several global senior positions in various biotech and pharma companies. Since 1996, he has focused his research activity on new formulation technologies and drug delivery systems; such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology, especially for injectable peptide and protein formulations. He graduated from Ecole Normale Supérieure, Cachan in 1985 and got a PhD in Materials Science from University of Paris VI in 1987. He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in fields like polymers, colloids and interfaces, drug delivery, supercritical fluids, protein formulations, nanoparticles, and sustained-release formulations. He is the Author of more than 120 international communications and 53 patent families.

Abstract

Due to their physicochemical characteristics, peptides are usually administered through the parenteral route, often several times daily. Injectable sustained-release peptide formulations based on biodegradable microparticles or implants have been very successful to enhance patient adherence and convenience, and increase safety and efficacy. They are likely to remain a significant and important part of the new peptide products coming to the market. However, the tremendous developments in alternative non-invasive routes of delivery are likely to result in more and more peptides being delivered by the transdermal, nasal, inhalation and oral routes. The main purpose of this talk will be to analyze and compare the various alternative non-invasive peptide delivery technologies progressing in the clinic, discussing the pros and cons of these technologies in regards to stability, bioavailability, safety/efficacy balance, impact on costs of goods and manufacturability. A special emphasis will be put on oral peptide technologies progressing successfully in the clinic, the key learning from ongoing clinical studies and the future challenges anticipated for filing and launching oral peptide products in the next years.